The aml Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the aml Hub cannot guarantee the accuracy of translated content. The aml and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The AML Hub is an independent medical education platform, sponsored by Astellas, Daiichi Sankyo, Johnson & Johnson, Kura Oncology and Syndax, and has been supported through educational grants from Bristol Myers Squibb and the Hippocrate Conference Institute, an association of the Servier Group. The funders are allowed no direct influence on our content. The levels of sponsorship listed are reflective of the amount of funding given. View funders.
Now you can support HCPs in making informed decisions for their patients
Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.
Find out more
Create an account and access these new features:
Bookmark content to read later
Select your specific areas of interest
View aml content recommended for you
Tamibarotene + Ven + Aza combination in patients with AML: Interim results from the SELECT-AML-1 phase II trial
|
During the SOHO 2024 Annual Meeting, Borate presented interim efficacy and safety results from the phase II SELECT-AML-1 trial (NCT04905407) of tamibarotene in combination with Ven and Aza in patients with newly diagnosed AML with RARA overexpression.1 A total of 51 patients were randomized to receive either tamibarotene + Ven + Aza (n = 25) or Ven + Aza (n = 26).1 |
| Key learnings |
|
The primary endpoint of CR/CRi was achieved in 60% in the tamibarotene + Ven + Aza group vs 69% in the Ven + Aza group, with a median duration of response of 293 months vs 253 months, respectively. ORR was 80% and 73%, respectively. |
|
In the prespecified efficacy futility analysis, CR/CRi was achieved in 65% of patients receiving tamibarotene + Ven + Aza (n = 20) vs 70% of patients receiving Ven + Aza (n = 20). ORR was 85% and 75%, respectively. |
|
The incidence of any grade TEAE was 100% in the tamibarotene + Ven + Aza group (n = 24) vs 89% in Ven + Aza group (n = 27). The most common non-hematologic TEAEs occurring in ≥25% of patients were constipation (42% vs 19%), diarrhea (38% vs 22%), nausea (33% vs 33%), peripheral edema (29% vs 11%), pruritus (29% vs 0%), weight loss (25% vs 11%), reduced appetite (21% vs 26%), and dyspnea (21% vs 26%). The addition of tamibarotene to Ven and Aza did not cause any additive myelosuppression. |
|
The findings suggest that the tamibarotene + Ven + Aza combination was well tolerated; however, it did not show any improvements in CR/CRi and ORR compared with Ven + Aza. The prespecified efficacy analysis showed similar response rates between the two groups. However, there remains an opportunity to evaluate the longer-term impact on the duration of response, survival, and salvage therapy. |
Abbreviations: AML, acute myeloid leukemia; Aza, azacitidine; CR, complete remission; CRi, complete remission with incomplete hematologic recovery; ORR, overall response rate; SOHO, Society of Hematologic Oncology; TEAE, treatment-emergent adverse event; Ven, venetoclax.
References
Please indicate your level of agreement with the following statements:
The content was clear and easy to understand
The content addressed the learning objectives
The content was relevant to my practice
I will change my clinical practice as a result of this content
Your opinion matters
Approximately what proportion of your patients with FLT3-mutations also have NPM1 and DNMT3A co-mutations?
